Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

Pharmaceutical company Merck (NYSE:MRK) is set to report its second quarter earnings on Tuesday, July 29th, before the ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

AI insights suggest a bullish near-term outlook for BMY. The risk-reward ratio heavily favors a long position, sitting pretty ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Many market-moving companies, such as Meta, Apple, and Amazon are reporting earnings this week. Click on any ticker below to ...

US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.